Heptares Therapeutics Ltd has announced the results of a Series B financing round in which it raised more than $21 million to advance a candidate product for Alzheimer’s dementia and disorders of cognitive impairment into the clinic. ---Subscribe to MedNous to access this article--- Company News Finance, Grants, Deals
